Abstract
Pure red cell aplasia (PRCA) can potentially occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT) if recipient and donor ABO blood groups are mismatched, with the recipient having isoagglutinins against the donor blood group. Patient plasma cells that survive transplant conditioning produce anti-ABO isoagglutinins targeting donor erythroid precursors in the bone marrow and thus causing red cell aplasia. Therapeutic options include steroids, discontinuation of immunosuppression, plasmapheresis, donor lymphocyte infusion, rituximab, and bortezomib, all with limited benefit. Daratumumab utilized in the treatment of multiple myeloma is an anti-CD38 monoclonal antibody targeting plasma cells, which makes it a potentially efficient therapy for PRCA. The current case report presents a patient with post-allo-HSCT PRCA cured with daratumumab applied after failure of other therapies. Our findings demonstrate safety and high efficiency of daratumumab, suggesting its applicability as early treatment of post-allo-HSCT PRCA.
References
1.
O’Donnel
MR
. Blood groups incompatebilities and hemolytic complications of hematopoietic cell transplantation
. In: Appelbaum
FR
, Forman
SJ
, Negrin
RS
, Blume
KG
, editors. Thomas’ hematopoietic cell transplantation
. Oxford
: Wiley-Blackwell
; 2008
. p. 1219
–25
.2.
Worel
N
, Greinix
HT
, Schneider
B
, Kurz
M
, Rabitsch
W
, Knöbl
P
, Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems
. Transfusion
. 2000 May
;40
(5
):543
–50
. .3.
Curley
C
, Pillai
E
, Mudie
K
, Western
R
, Hutchins
C
, Durrant
S
, Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange
. Transfusion
. 2012 Feb
;52
(2
):291
–7
. .4.
Verholen
F
, Stalder
M
, Helg
C
, Chalandon
Y
. Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion
. Eur J Haematol
. 2004 Dec
;73
(6
):441
–6
. .5.
Helbig
G
, Stella-Holowiecka
B
, Krawczyk-Kulis
M
, Wojnar
J
, Markiewicz
M
, Wojciechowska-Sadus
M
, Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia
. Haematologica
. 2005 Nov
;90
(Suppl
):ECR33
.6.
Sora
F
, De Matteis
S
, Piccirillo
N
, Chiusolo
P
, Laurenti
L
, Putzulu
R
, Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation
. Transfusion
. 2005 Apr
;45
(4
):643
–5
.7.
Khan
F
, Linden
MA
, Zantek
ND
, Vercellotti
GM
. Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation
. Transfus Med
. 2014 Jun
;24
(3
):187
–8
. .8.
Dellacasa
CM
, D’Ardia
S
, Allione
B
, Aydin
S
, Tassi
V
, Francisci
T
, Efficacy of plasmapheresis for the treatment of pure red blood cell aplasia after allogeneic stem cell transplantation
. Transfusion
. 2015 Dec
;55
(12
):2979
–82
. .9.
Hiroshima
Y
, Shiono
Y
, Suzuki
I
, Yamamoto
M
, Kato
Y
, Tajima
K
, Successful high-dose dexamethasone treatment of acquired pure red cell aplasia following ABO major mismatched allogeneic hematopoietic stem cell transplantation
. Rinsho Ketsueki
. 2016 Jun
;57
(6
):760
–4
. .10.
Busca
A
, Dellacasa
C
, Giaccone
L
, Manetta
S
, Biale
L
, Godio
L
, Eltrombopag for the treatment of refractory pure RBC aplasia after major ABO incompatible hematopoietic stem cell transplantation
. Biol Blood Marrow Transplant
. 2018 Aug
;24
(8
):1765
–70
. .11.
Bonello
F
, Mina
R
, Boccadoro
M
, Gay
F
. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma
. Cancers
. 2019 Dec 19
;12
(1
):15
.12.
Chapuy
CI
, Kaufman
RM
, Alyea
EP
, Connors
JM
. Daratumumab for delayed red-cell engraftment after allogeneic transplantation
. N Engl J Med
. 2018 Nov 8
;379
(19
):1846
–50
. .13.
Bathini
S
, Holtzman
NG
, Koka
R
, Singh
Z
, Wilding
E
, Zou
Y
, Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab
. Am J Hematol
. 2019 Aug
;94
(8
):E216
–E19
. .14.
Jeyaraman
P
, Borah
P
, Rajput
P
, Dayal
N
, Pathak
S
, Naithani
R
. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia
. Blood Cells Mol Dis
. 2020 Jul 2
;88
:102464
. .15.
Rautenberg
C
, Kaivers
J
, Germing
U
, Haas
R
, Ackerstaff
S
, Hoffmann
T
, Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation
. Bone Marrow Transplant
. 2020 Jun
;55
(6
):1191
–3
. .16.
Salas
MQ
, Alahmari
A
, Lipton
JH
. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab
. Eur J Haematol
. 2020 Feb
;104
(2
):145
–7
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
